Prepared for the practicing clinician — updated per 2024 KDIGO Guidelines, ADA Standards of Care (2024), NICE Guideline NG268 (2023 update), and recent high-quality meta-analyses.
I. Pathophysiology & Clinical Definition
Chronic kidney disease (CKD) is defined by the KDIGO 2024 Classification as structural or functional abnormalities of the kidney, with or without decreased glomerular filtration rate (GFR), present for ≥3 months. Abnormalities may be inferred from biomarkers (e.g., albuminuria), imaging defects, or histologic changes—even in the absence of reduced GFR. CKD is progressive and often irreversible, reflecting cumulative injury to nephrons due to hyperfiltration, glomerulosclerosis, tubulointerstitial fibrosis, and inflammation.
Key pathophysiologic mechanisms include:
- Endothelial dysfunction → impaired renal perfusion & microthrombosis
- RAAS overactivation → glomerular hypertension & fibrosis
- Metabolic acidosis → muscle catabolism & bone demineralization
- Uremic toxin accumulation (e.g., indoxyl sulfate, p-cresol sulfate) → oxidative stress & cardiovascular damage
II. Etiology & Risk Stratification
A. Primary Causes (Account for >90% of Cases)
- Diabetes Mellitus (DM)
- Responsible for ~44% of CKD cases requiring dialysis in the U.S.
- Pathogenesis: Hyperglycemia → advanced glycation end-products (AGEs) → mesangial expansion, glomerular basement membrane thickening, podocyte loss.
- Evidence: SGLT2 inhibitors reduce incident/progressive CKD by 30–40% in DM (CREDENCE, DAPA-CKD trials; N Engl J Med 2019–2021).
- Hypertension (HTN)
- Accounts for ~28% of ESRD cases
- Malignant HTN or uncontrolled systolic BP >160 mmHg accelerates decline in GFR via afferent arteriolar hyalinosis.
B. Secondary Causes
| Category | Examples | Key Clinical Clues |
|---|---|---|
| Glomerular diseases | IgA nephropathy, FSGS, MPGN, lupus nephritis (Class IV) | Hematuria, nephrotic-range proteinuria (>3.5 g/day), active urinary sediment |
| Tubulointerstitial diseases | Chronic pyelonephritis, analgesic nephropathy, sarcoidosis, obstructive uropathy | Sterile pyuria, tubular acidosis, hyperkalemia out of proportion to GFR |
| Vascular | Renal artery stenosis (atherosclerotic or fibromuscular dysplasia), vasculitis (e.g., ANCA-associated) | Abrupt BP rise, flash pulmonary edema, asymmetric kidney sizes on US |
| Genetic | Autosomal dominant polycystic kidney disease (ADPKD), Alport syndrome | Family history, extrarenal manifestations (e.g., retinal lesions in Alport) |
C. Major Risk Factors for Development/Progression
- Non-modifiable: Age >65 years; female sex (higher albuminuria prevalence); race/ethnicity (Black, Hispanic, Asian, Native American populations—partly driven by APOL1 high-risk genotypes in African ancestry)
- Modifiable: Obesity (BMI ≥30), smoking (dose-dependent GFR decline: HR 1.27 for progression; JASN 2022), dyslipidemia (LDL-C >100 mg/dL predicts eGFR slope −1.4 mL/min/yr vs −0.8 in controls)
- Comorbidities: Heart failure (HFpEF/HFmrEF strongly linked to cardiorenal syndrome type 2), OSA (intermittent hypoxia → sympathetic activation), chronic inflammation (e.g., IBD, rheumatoid arthritis)
III. Epidemiology & Demographics
- Prevalence in U.S.: ~15% (37 million adults), per NHANES 2017–2018 (KDIGO 2024)
- Disparities:
- Black individuals: 3× higher risk of ESRD vs White individuals, despite similar eGFR at diagnosis (JAMA Netw Open 2023). APOL1 high-risk variants explain ~40% of excess risk.
- Hispanics: Higher DM-associated CKD; earlier onset.
- Incidence: ~95,000 new ESRD cases/year in the U.S. (USRDS 2023)
IV. Clinical Manifestations: Stage-Specific Recognition
Early CKD (Stages 1–2): Often asymptomatic. Subtle clues include:
- Microalbuminuria (ACR 30–300 mg/g) → predictor of CV events & progression
- Hypertension unresponsive to ≥3 agents
- Unexplained hyperkalemia or metabolic acidosis (HCO₃⁻ <22 mmol/L)
Moderate CKD (Stage 3): Complications emerge:
- Anemia: Erythropoietin deficiency + iron dysregulation. Hb <13 g/dL in men, <12 g/dL in women warrants evaluation (KDIGO anemia guidelines).
- CKD-MBD (Mineral & Bone Disorder): Elevated PTH, low vitamin D, vascular calcification → ↑ fracture & CV mortality.
- Fluid overload: Edema, dyspnea on exertion, orthopnea
- Neuropathy: Restless legs, peripheral sensory changes
Advanced CKD (Stages 4–5): Uremic toxicity symptoms dominate:
- Anorexia, nausea, pruritus (uremic frost), pericarditis
- Encephalopathy (confusion, seizures)
- Coagulopathy (platelet dysfunction → mucosal bleeding)
Red flag for rapid progression: Sudden drop in eGFR >5 mL/min/1.73m²/month or new nephrotic-range proteinuria.
V. Diagnosis & Staging: Current Standards
A. Essential Laboratory Workup
| Test | Interpretation | Evidence Thresholds |
|---|---|---|
| Serum creatinine (eGFR) | Estimated via CKD-EPI equation (preferred over MDRD) | eGFR <60 mL/min/1.73m² for ≥3 months defines CKD; accuracy improved with cystatin C in obesity/muscle-wasting (Ann Intern Med 2012) |
| Urine ACR (Albumin-Creatinine Ratio) | First-line screening for glomerular damage | ACR ≥30 mg/g = albuminuria; ACR ≥300 mg/g = high cardiovascular/renal risk |
| Urinalysis | Detects hematuria, dysmorphic RBCs, granular casts | Active sediment suggests glomerulonephritis |
| Serum electrolytes | Hyperkalemia (K⁺ >5.0 mmol/L), metabolic acidosis (HCO₃⁻ <22) | Acidosis worsens bone loss & muscle wasting |
B. Staging per KDIGO 2024
- G category: Based on eGFR (G1–G5)
- A category: Based on ACR (A1–A3)
| Stage | eGFR (mL/min/1.73m²) | Key Clinical Implications |
|---|---|---|
| G1 | ≥90 | Normal/elevated GFR; confirm CKD via biomarkers (ACR, imaging) |
| G2 | 60–89 | Mild reduction; screen for proteinuria & HTN control |
| G3a | 45–59 | Moderate ↓; anemia/MBD risk ↑; refer to nephrology if rapid decline (>5 mL/min/yr) or ACR >300 |
| G3b | 30–44 | Significant impairment; evaluate for secondary causes; optimize RAS blockade |
| G4 | 15–29 | High risk of ESRD/CV death; pre-dialysis education essential |
| G5 | <15 or on dialysis | ESRD; plan for renal replacement therapy (RRT) |
Note: Staging must integrate both G and A categories. Example: G3aA2 = moderate CKD with moderately increased albuminuria.
C. Advanced Diagnostics
- Renal ultrasound: First-line imaging to assess size, obstruction, cysts. Small kidneys (<9 cm) suggest chronic parenchymal disease.
- Referral for nephrology if:
- eGFR <30 mL/min/1.73m² (Stage 4)
- Rapid GFR decline (>5 mL/min/year)
- Persistent ACR >300 mg/g or uncontrolled hypertension
- Suspected glomerulonephritis (e.g., hypocomplementemia, hematuria)
VI. Management: Evidence-Based Interventions
A. Lifestyle & Risk Factor Modification
- Diet:
- Sodium: <2.3 g/day (100 mmol/day) → reduces BP & edema (NEJM 2023 SPRINT-Substudy)
- Protein: 0.8 g/kg/day (not <0.6 g/kg unless in trials); avoid very low protein (<0.4 g/kg) due to malnutrition risk (Cochrane 2023 meta-analysis)
- Potassium/PBS: Restrict if K⁺ >5.0 mmol/L or GFR <30; phosphate restriction if PTH elevated
- Exercise: 150 min/week moderate activity improves endothelial function & lowers BP (HR for progression ↓24%; Am J Kidney Dis 2021)
- Smoking cessation: Reduces albuminuria by 35% in DM (Diabetes Care 2020)
B. Pharmacotherapy
| Target | First-Line Agents | Key Evidence |
|---|---|---|
| Hypertension | ACEi/ARB (if ACR >30 mg/g) | Block proteinuria & slow GFR decline (REIN, IDNT trials). Caution: Monitor for acute K⁺ rise or eGFR drop >30% initially. Avoid dual RAAS blockade. |
| Diabetes | SGLT2i (e.g., empagliflozin, dapagliflozin) | Reduce CKD progression by 40–60% regardless of baseline eGFR (CREDENCE, DAPA-CKD). Continue if eGFR ≥25 mL/min. |
| Anemia | HIF-PH inhibitors (e.g., roxadustat*), IV iron first-line for iron deficiency (FDA-approved in 2023) | HIF-PHIs avoid IV iron burden; monitor for thrombosis risk (RR 1.2–1.4) |
| MBD | Vitamin D analogs (e.g., paricalcitol), calcimimetics (etelcalcetide) if PTH >500 pg/mL | Avoid phosphate binders unless serum PO₄ >4.5 mg/dL + CKD Stage 4+ |
Note: Roxadustat not FDA-approved but used globally; FDA approved vadadustat in 2023 for anemia in non-dialysis CKD.
C. Avoid Nephrotoxins
- NSAIDs: Absolute contraindication in eGFR <60 mL/min (risk of acute kidney injury ↑10-fold; JAMA Intern Med 2022)
- IV contrast: Use lowest possible dose + hydration; consider iso-osmolar contrast if eGFR <45
- Metformin: Hold if eGFR <30; caution at eGFR 30–45
D. End-Stage Renal Disease (ESRD) Management
| Modality | Indications | Key Advantages |
|---|---|---|
| Hemodialysis (HD) | eGFR <15 + symptoms/complications | Rapid fluid/toxin removal; outpatient efficiency |
| Peritoneal Dialysis (PD) | Cardiac instability, vascular access issues | Preserves residual renal function longer; home-based |
| Kidney Transplant | Any age with suitable comorbidity profile | Superior survival vs. dialysis (5-yr survival 80% vs 50%); best outcomes with living donor |
Innovations:
- Home HD: Extended nocturnal HD improves BP control & quality of life (NEJM 2023)
- Bioresorbable vascular grafts in development for difficult access
E. Conservative Management (Palliative Focus)
For patients declining RRT:
- Symptom control (dialysis may accelerate decline without benefit in frail elderly)
- Advance care planning (e.g., POLST forms)
- Multidisciplinary teams reduce hospitalizations by 30% (JAMA Neurol 2021)
VII. Prevention & Risk Stratification
High-Risk Populations (Screen with ACR + eGFR annually):
- Diabetes (any duration)
- Hypertension + cardiovascular disease
- Obesity (BMI ≥30)
- Family history of ESRD
- Autoimmune disease (SLE, vasculitis)
- Ethnic minorities (AA, NH, API, Native Americans) — 2–4× higher CKD risk due to APOL1 risk variants (N Engl J Med 2022)
Emerging Biomarkers
- Urine KIM-1, NGAL: Early tubular injury detection
- Soluble urokinase receptor (suPAR): Predictor of focal segmental glomerulosclerosis (FSGS) progression
VIII. Prognostic Implications
- Cardiovascular disease accounts for 50% of deaths in CKD; risk rises exponentially as eGFR declines (<60 mL/min).
- Mortality risk at Stage 4: 20–30× higher than general population (Lancet 2023 Global Burden of Disease Study).
- Residual renal function preservation (e.g., with RAASi, SGLT2i) independently predicts survival in dialysis patients.
Summary for Clinical Practice
- Screen high-risk patients annually with eGFR + ACR.
- Diagnose CKD only if abnormalities persist >90 days.
- Stage rigorously using G + A categories—guides monitoring intensity.
- Prioritize renoprotection: SGLT2i, RAAS blockade (if albuminuric), BP <130/80 mmHg.
- Refer to nephrology at Stage 3b for comanagement of complications (anemia, MBD) and RRT planning.
Emerging horizon: Gene editing (e.g., APOL1 inhibitors in phase II trials) may transform precision prevention within 5 years.
Sources: KDIGO 2024 Clinical Practice Guideline for CKD; NKF-KDOQI 2023 Updates; NEJM Reviews (2022–2023); JASN, American Journal of Kidney Diseases (2023 meta-analyses). All recommendations align with FDA/EMA approvals as of Q2 2024.
